Anne Marie Reimer Jensen

Dr. Anne Marie Reimer Jensen

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
JCJacob Christensen
Jacob Christensen
NJNiklas Dyrby Johansen
Niklas Dyrby Johansen
DMDaniel Modin
Daniel Modin
KJKira Hyldekær Janstrup
Kira Hyldekær Janstrup
JNJoshua Nealon
Joshua Nealon
TBTor Biering-Sørensen
Tor Biering-Sørensen
BACKGROUND: Influenza vaccination reduces the risk of adverse outcomes in patients with cardiovascular disease (CVD). We sought to evaluate whether the presence of CVD modified the relative effectiveness of the high-dose quadrivalent influenza vaccine (QIV-HD) versus standard-dose quadrivalent influenza vaccine (QIV-SD) in this prespecified analysis of the DANFLU-1 trial (Feasibility of Randomizing Danish Citizens Aged 65–79 Years to High-Dose Quadrivalent Influenza Vaccine Versus Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting). METHODS: DANFLU-1 was a pragmatic, open-label, randomized feasibility trial of QIV-HD versus QIV-SD in adults aged 65 to 79 years during the 2021/2022 influenza season in Denmark. Vaccines were allocated in a 1:1 ratio. Baseline and follow-up data regarding diagnoses and mortality were obtained from Danish national registers. The trial is registered at Clinicaltrials.gov: NCT05048589. The CVDs assessed included heart failure, ischemic heart disease, atrial fibrillation, and a combined group denoted chronic CVD consisting of the aforementioned diseases, among others. Prespecified outcomes included hospitalizations for pneumonia or influenza, respiratory disease, CVD, cardiorespiratory disease, all-cause hospitalizations, and mortality. Effect modification was tested using interaction terms. RESULTS: The final study population included 12 477 participants (mean age of 71.7±3.9 years and 5877 [47.1%] were female), of whom 2540 (20.4%) had chronic CVD. QIV-HD versus QIV-SD was associated with a lower incidence of hospitalizations for pneumonia or influenza (incidence rate ratio [IRR], 0.30 [95% CI, 0.14–0.64]) and all-cause mortality (IRR, 0.51 [95% CI, 0.30–0.86]) regardless of chronic CVD ( P interaction =0.57 and 0.49, respectively). The relative effectiveness of QIV-HD versus QIV-SD against all-cause hospitalizations was modified in participants with chronic CVD (overall: IRR, 0.87 [95% CI, 0.76–0.99]; no chronic CVD: IRR, 0.79 [95% CI, 0.67–0.92]; chronic CVD: IRR, 1.11 [95% CI, 0.88–1.39]; P interaction =0.026). No other effect modification was observed by the presence of chronic CVD, heart failure, ischemic heart disease, or atrial fibrillation. CONCLUSIONS: The relative effectiveness of QIV-HD versus QIV-SD was consistent against hospitalizations for pneumonia or influenza and all-cause mortality regardless of chronic CVD. However, the relative effectiveness against all-cause hospitalizations was modified by the presence of chronic CVD. These results should be considered hypothesis generating. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05048589.

30 August 2025 in JACC
Verified
Journal Article
Open access
KSKristoffer Grundtvig Skaarup
Kristoffer Grundtvig Skaarup
MLMats C. Højbjerg Lassen
Mats C. Højbjerg Lassen
NJNiklas Dyrby Johansen
Niklas Dyrby Johansen
SCSine H. Christensen
Sine H. Christensen
NANegar Aliabadi
Negar Aliabadi
TBTor Biering-Sørensen
Tor Biering-Sørensen

1 November 2025 in Circulation: Heart Failure
Verified
Journal Article
Closed access
KSKristoffer Grundtvig Skaarup
Kristoffer Grundtvig Skaarup
NJNiklas Dyrby Johansen
Niklas Dyrby Johansen
DMDaniel Modin
Daniel Modin
MLMatthew M. Loiacono
Matthew M. Loiacono
RHRebecca Harris
Rebecca Harris
TBTor Biering-Sørensen
Tor Biering-Sørensen
BACKGROUND: Influenza contributes substantially to disease burden in individuals with heart failure (HF) and is an established trigger of cardiovascular and HF events. Standard-dose inactivated influenza vaccine (SD-IIV) is recommended for HF, though immune responses may be attenuated. High-dose inactivated influenza vaccine (HD-IIV) was developed to enhance immunogenicity, but its effectiveness compared with SD-IIV against hospitalization for influenza and cardiovascular disease by HF status remains uncertain. METHODS: This was a prespecified analysis of a pragmatic, prospective, individually randomized, open-label trial with registry-based end point-evaluation conducted in Denmark across the 2022/2023 to 2024/2025 influenza seasons. Citizens ≥65 years were randomized 1:1 to HD-IIV or SD-IIV. Outcomes included hospitalization for influenza-related illness, laboratory-confirmed influenza, any cardiovascular disease, cardio-respiratory disease, and HF, assessed by HF status. Effect of HD-IIV versus SD-IIV in reducing risk of outcomes assessed was expressed as risk ratios. RESULTS: The trial randomized 332 438 participants (48.6% female; mean age, 73.7±5.8 years), including 10 410 with HF at baseline (27.4% female; mean age, 76.0±6.3 years). Overall, HD-IIV was associated with a statistically significant lower incidence of hospitalization for influenza-related illness, laboratory-confirmed influenza, cardio-respiratory disease, cardiovascular disease, and HF compared with SD-IIV. In participants with HF, effect estimates were similar: risk ratio for influenza-related hospitalization was 0.48 (95% CI, 0.20–1.06; P interaction =0.64), for laboratory-confirmed influenza hospitalization 0.55 (95% CI, 0.29–1.02; P interaction =0.59), for cardio-respiratory hospitalization 0.89 (95% CI, 0.77–1.02; P interaction =0.34), for cardiovascular hospitalization 0.86 (95% CI, 0.72–1.02; P interaction =0.34), and for HF hospitalization 0.82 (95% CI, 0.61–1.11; P interaction =0.83). Findings were consistent across HF subgroups by disease duration, recency of hospitalization, most recent NT-proBNP (N-terminal pro-B-type natriuretic peptide), and presence of device therapy. CONCLUSIONS: In this prespecified exploratory analysis of the largest individually randomized influenza vaccine trial ever conducted, HD-IIV was associated with lower rates of influenza and cardiovascular hospitalizations compared with SD-IIV, with effect estimates similar across HF status at baseline and HF subgroups. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: https://clinicaltrials.gov/study/NCT05517174 .

30 August 2024 in JACC
Verified
Journal Article
Closed access
KBKatja Vu Bartholdy
Katja Vu Bartholdy
NJNiklas Dyrby Johansen
Niklas Dyrby Johansen
KJKira Hyldekær Janstrup
Kira Hyldekær Janstrup
DMDaniel Modin
Daniel Modin
JNJoshua Nealon
Joshua Nealon
TBTor Biering-Sørensen
Tor Biering-Sørensen

26 November 2025 in JACC
Verified
Journal Article
Open access
KBKatja Vu Bartholdy
Katja Vu Bartholdy
NJNiklas Dyrby Johansen
Niklas Dyrby Johansen
DMDaniel Modin
Daniel Modin
MLMatthew M. Loiacono
Matthew M. Loiacono
RHRebecca C. Harris
Rebecca C. Harris
TBTor Biering-Sørensen
Tor Biering-Sørensen
Influenza-related complications occur frequently in persons with chronic kidney disease (CKD). Limited data exist on the effectiveness of high-dose inactivated influenza vaccine (HD-IIV) in persons with CKD. The purpose of this study was to assess the relative effectiveness (rVE) of HD-IIV vs standard-dose inactivated influenza vaccine (SD-IIV) against severe clinical outcomes in persons with CKD from the elderly general population. DANFLU-2 (A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Influenza Vaccine vs. Standard-Dose Influenza Vaccine in Older Adults) was a pragmatic, open-label, individually randomized trial conducted in Denmark during the 2022-2023, 2023-2024, and 2024-2025 influenza seasons with the aim of assessing the rVE of HD-IIV vs SD-IIV in an older adult general population. In this prespecified secondary analysis, we assessed the rVE against severe clinical outcomes according to the presence of CKD. CKD was defined using data from laboratory registries and International Classification of Diseases-10th Revision diagnosis codes 10 years before vaccination. Among 332,438 DANFLU-2 participants (mean age 73.7 ± 5.8 years; 48.6% women), 46,788 (14.1%) had CKD at baseline. The effect of HD-IIV vs SD-IIV on hospitalization for influenza or pneumonia differed by CKD status: rVE was 16.9% (95% CI: 3.4%-28.5%) in participants with CKD vs 0.6% (95% CI: -9.6% to 9.9%) in those without CKD (P interaction = 0.046). Absolute risks for hospitalization for influenza or pneumonia were 1.7% with SD-IIV vs 1.3% with HD-IIV in CKD, corresponding to an absolute risk reduction of -0.29% (95% CI: -0.50% to 0.058%; number needed to treat [NNT] = 359). For influenza hospitalizations specifically, the benefit of HD-IIV was also substantially greater in CKD: rVE 68.6% (95% CI: 46.7%-82.3%; NNT = 561) vs 30.6% (95% CI: 7.2%-48.2%; NNT =3,953) in non-CKD (P interaction = 0.0079). Reductions in hospitalizations for cardiorespiratory disease, cardiovascular disease, heart failure, and laboratory-confirmed influenza were consistent regardless of CKD (all P interaction > 0.05). In this prespecified analysis of DANFLU-2, including the largest CKD population ever in an individually randomized vaccine trial, we observed a benefit of HD-IIV vs SD-IIV against hospitalization for influenza or pneumonia, as well as hospitalization for influenza, with suggestion of a greater relative benefit among those with CKD. Furthermore, the beneficial effect of HD-IIV vs SD-IIV on multiple cardiorespiratory outcomes was consistent across participants irrespective of CKD status.

13 August 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
CECaroline Espersen
Caroline Espersen
NJNiklas Dyrby Johansen
Niklas Dyrby Johansen
DMDaniel Modin
Daniel Modin
KJKira Hyldekær Janstrup
Kira Hyldekær Janstrup
JNJoshua Nealon
Joshua Nealon
TBTor Biering-Sørensen
Tor Biering-Sørensen
Background: Frailty is a risk factor for adverse influenza-related outcomes. We assessed the effectiveness of high-dose inactivated influenza vaccination (HD-IIV) versus standard-dose inactivated influenza vaccination (SD-IIV) according to a frailty score. Methods: This was a post hoc analysis of the randomized feasibility trial of HD-IIV versus SD-IIV conducted during the 2021–2022 influenza season in older adults aged 65–79 years. We assessed prespecified outcomes, including hospitalizations and deaths, as first and recurrent events. Frailty was defined according to the hospital frailty risk score (HFRS). Results: Among 12 477 included participants (mean age, 71.7 years; 47.1% female), 10 689 (85.7%) were categorized as having low frailty (HFRS <5) and 1784 (14.3%) had intermediate or high frailty (HFRS ≥5). HD-IIV versus SD-IIV was associated with a lower risk of first and recurrent hospitalizations for pneumonia or influenza regardless of the HFRS. For participants with low frailty there were 22 events (hazard ratio [HR], 0.37 [95% confidence interval, .15–.96]) and 25 recurrent events (incidence rate ratio, 0.31 [.11–.84]), and for those with intermediate or high frailty there were 16 events (HR, 0.33 [.11–1.01]) and 18 recurrent events (incidence rate ratio, 0.28 [.09–.92]; P value for continuous interaction with HFRS [Pinteraction] = .92 for first and Pinteraction = .93 for recurrent events). The HFRS modified the association of HD-IIV versus SD-IIV with all-cause mortality (Pinteraction = .02), with an association with reduced risk in participants with low frailty only (43 events, HR, 0.26 [95% confidence interval, .13–.55]). Conclusions: HD-IIV was associated with a lower risk of first and recurrent hospitalizations for pneumonia and influenza compared with SD-IIV and may be preferred for older adults, irrespective of frailty status. The HFRS modified the association of HD-IIV versus SD-IIV with all-cause mortality.